Clinical trial looks at potential vaccine for Alzheimer’s disease
Published 31 December 2015
A new clinical trial is underway to look at a potential vaccine that targets tau protein in the brains of people with Alzheimer’s disease.
Alzheimer’s is caused when proteins called amyloid and tau clump together in the brain – known as plaques and tangles respectively – and cause damage to cells. Current treatments for Alzheimer’s disease focus on improving the symptoms, but few are able to slow the progression of the condition.
Scientists at the Research Institute for the Care of Older People (RICE) are hoping that a new drug will act as a vaccine; targeting tau tangles in the brain to prevent their build-up potentially remove them altogether. The clinical trial will look at whether the drug is safe for people with mild to moderate Alzheimer’s disease to use. The researchers hope that it could potentially slow or halt the progression of the condition.
Dr James Pickett, Head of Research at Alzheimer’s Society said:
'So far, most clinical trials have focused on amyloid protein, which can be responsible for brain cell death and some Alzheimer’s disease symptoms, but this potential drug is targeted at tau protein tangles, that may be linked with memory loss.
'The researchers are hoping that this could possibly be used as a vaccine, causing the body’s immune system to attack the tau tangles. Although researchers are now looking at whether the vaccine is safe for people to use, it will be several years until we know if it will be able to improve the lives of people with Alzheimer’s disease.
'With an ageing population and no new dementia drugs in over a decade, the need to find new treatments is more urgent than ever. We need more people to come forward to get involved with scientific studies. Join Dementia Research is an NHS service that allows people to register their interest and find suitable research they can take part in.'